Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently
identified autoimmune disorder that presents in both adults and children as CNS …

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is the
most recently defined inflammatory demyelinating disease of the central nervous system …

In the past 15 years, B cells have been rediscovered to be not merely bystanders but rather
active participants in autoimmune aetiology. This has been fuelled in part by the clinical …

Neuromyelitis optica (NMO) is a chronic inflammatory autoimmune disease of the central
nervous system (CNS) characterized by acute optic neuritis (ON) and transverse myelitis …

The realization that autoantibodies can contribute to dysfunction of the brain has brought
about a paradigm shift in neurological diseases over the past decade, offering up important …

Abstract IgG4-related disease (IgG4-RD) has only existed as a unique disease entity since
2003, yet remarkable progress has already been achieved in describing the essential …

Background Satralizumab, a humanised monoclonal antibody targeting the interleukin-6
receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder …

This 2020 installment of the annual 'Antibodies to Watch'series documents the antibody
therapeutics approved in 2019 and in regulatory review in the United States or European …

Background Pharmacological prevention against relapses in patients with neuromyelitis
optica spectrum disorder (NMOSD) is developing rapidly. We aimed to investigate the safety …

The term 'neuromyelitis optica spectrum disorders'(NMOSD) is used as an umbrella term that
refers to aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica (NMO) …